Navigation Links
Kendle to Present at the 29th Annual Raymond James Institutional Investors Conference
Date:2/29/2008

CINCINNATI, Feb. 29 /PRNewswire-FirstCall/ -- Kendle (Nasdaq: KNDL), a leading, global full-service clinical research organization, today announced that Vice President and Chief Marketing Officer Simon Higginbotham will participate in the 29th Annual Raymond James Institutional Investors Conference. The conference will be held at the Hyatt Regency Grand Cypress in Orlando, March 2-5, 2008. Kendle's presentation is scheduled for Wednesday, March 5 at 1:40 p.m. Eastern Time.

(Logo: http://www.newscom.com/cgi-bin/prnh/20030429/KNDLLOGO )

The public is invited to listen to a live webcast of Kendle's presentation at http://www.kendle.com (click on the link provided in the Investor Events section) or at http://www.wsw.com/webcast/rj33/kndl/. An archived version can be accessed following Kendle's presentation and will be available through April 4. Slides accompanying the presentation will be available by 9 a.m. Eastern Time on March 5 at http://www.kendle.com in the Investor Relations section.

About Kendle

Kendle International Inc. (Nasdaq: KNDL) is among the world's leading global clinical research organizations. We deliver innovative and robust clinical development solutions -- from first-in-human studies through market launch and surveillance -- to help the world's biopharmaceutical companies maximize product life cycles and grow market share.

Our global clinical development business is focused on five regions -- North America, Europe, Asia/Pacific, Latin America and Africa -- to meet customer needs. We have conducted clinical trials and provided regulatory and pharmacovigilance services in more than 80 countries. Kendle was named "Top CRO to Work With" in the Thomson CenterWatch 2007 survey of U.S. investigative sites and "Best CRO" for 2007 and 2006 by leading global pharmaceutical publication Scrip.

Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 1200, Cincinnati, OH 45202 or from the Company's Web site at http://www.kendle.com.


'/>"/>
SOURCE Kendle International Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Kendle Hires Satish Tripathi, PhD, RAC as Vice President, Global Regulatory and Quality
2. Kendle to Present at the Wachovia 2008 Healthcare Conference
3. Kendle Appoints Former MHRA Head of Biologics as Principal Regulatory Affairs Consultant
4. Kendle Named Best CRO for Second Consecutive Year by Leading Global Pharmaceutical Publication Scrip
5. Kendle Invites You to Attend Its Third Quarter 2007 Earnings Conference Call and Webcast
6. Kendle to Present at the Natixis Bleichroeder Hidden Gems Conference
7. Kendle to Present at the UBS Global Life Sciences Conference
8. Kendle to Present at Bear Stearns 20th Annual Healthcare Conference
9. Kendle to Present at Thomas Weisel Partners Healthcare Conference 2007
10. Kendle Marks 10th Anniversary as Public Company With NASDAQ Opening Bell Ceremony and Investor Day Event
11. Kendle to Ring Opening Bell at NASDAQ Stock Market on August 22
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... 23, 2017 Research and Markets has ... report to their offering. ... The Global Market for Bioproducts ... 2016 at a CAGR of 8.9%, This ... bioproducts into seven major product segments: bio-derived chemicals, biofuels, pharmaceuticals ...
(Date:3/23/2017)...  GlobeImmune, Inc. today announced it has entered into ... shares of its common stock to NantCell, Inc., a ... the sale of its common stock, NantCell has agreed ... GlobeImmune 200,000 shares, an estimated $2.0 million in value, ... pleased to enter into this strategic agreement with NantCell," ...
(Date:3/23/2017)... , March 23, 2017 Kineta, ... development of novel therapies in immuno-oncology, today announced ... lead" small molecule compounds that activate interferon response ... pathways and demonstrate immune-mediated tumor regression in a ... the study who demonstrated complete tumor regression to ...
(Date:3/23/2017)... , March 23, 2017  Agriculture technology company Cool ... financing and note conversion to commercialize its Cool Terra ... focused on developing products that are simultaneously profitable as ... in the last 18 months. This latest round of ... Venture Partners. The company,s primary product, ...
Breaking Biology Technology:
(Date:2/22/2017)... -- With the biometrics market to exceed $10 ... that innovative and agile startups must incorporate into ... changing competitive landscape: multifactor authentication (MFA), point-of-sale (PoS), ... "Companies can no longer afford to cut corners ... Pavlakis , Industry Analyst at ABI Research. "Pairing ...
(Date:2/21/2017)... LONDON , February 21, 2017 ... um 70 Millionen US-Dollar wachsen. Nach einem Gespräch mit mehr ... es einige Hindernisse zu überwinden gilt, um diese Prognose ... ... unter anderem die Mobilisierung der finanziellen Mittel für die ...
(Date:2/14/2017)... , Feb. 14, 2017  Wake Forest Baptist Medical ... its new chief executive officer (CEO). Freischlag joins the ... John D. McConnell , M.D., who last year announced ... the Medical Center, after leading it since 2008.   ... scope of Wake Forest Baptist,s academic health system, which ...
Breaking Biology News(10 mins):